Study of Two Doses of Oral HDV-Insulin and Placebo With Background Metformin Treatment in Patients With Type 2 Diabetes Mellitus
Primary Purpose
Diabetes
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
placebo
Oral Hepatic Directed Vesicles (HDV)-Insulin (U-15)
Oral Hepatic Directed Vesicles (HDV)-Insulin (U-5)
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes focused on measuring Type 2
Eligibility Criteria
Inclusion Criteria:
- Age 18 to 70 years, inclusive;
- Diagnosis of type 2 diabetes mellitus;
- Fasting plasma glucose <=250 mg/dL;
- BMI <=45 kg/m2;
- HbA1c levels as follows at Screening:
- On a stable dose of metformin monotherapy with an HbA1c >=7.5% and <=9.5%;
- On metformin and 1 other OAD (excluding TZD, exenatide, or insulin) with an HbA1c >=6.8% and <=9.0%;
- Naïve to antidiabetic therapy or have not been on a stable dose of metformin monotherapy for <12 weeks with an HbA1c >=8.0% and <=10.5%;
- Understanding of the study procedures and agreement to participate in the study, giving written informed consent;
- Women may be enrolled if all of the following criteria (in addition to the above criteria) are met:
- They are not pregnant (women of childbearing potential must have a negative serum pregnancy test at Visit 1);
- They are not breast-feeding;
- They do not plan to become pregnant during the study; and
- They have had a hysterectomy or tubal ligation 6 months prior to the study, have been post-menopausal for 1 year, or will practice a method of birth control throughout the study.
Exclusion Criteria:
- History of type 1 diabetes and/or history of ketoacidosis;
- History of chronic (>2 months) use of insulin therapy or recent initiation of insulin use intended for chronic administration;
- Use of TZD (pioglitazone or rosiglitazone) or exenatide within 3 months prior to Screening;
- Use of prescription or over the counter weight loss agents within 1 month prior to Screening;
- Use of any lipid-altering, antihypertensive, and other chronic use medication not stable for 1 month prior to Screening;
- Use of any medication that may alter blood glucose analyses;
- Any serious disorder including cardiac, pulmonary, hepatic, uncontrolled endocrine/metabolic, hematologic/oncologic (within the last 5 years), neurologic, and psychiatric diseases that would interfere with the conduct of the study or interpretation of the data;
- Require regular use of medication that interferes with the oral absorption and/or metabolism of insulin or metformin;
- History of pancreatitis;
- History of acquired immune deficiency syndrome or human immunodeficiency virus;
- History of drug or alcohol abuse within the past 2 years;
- Hospitalization for any cause within 14 days prior to the study;
- History of an allergic or toxic response to oral HDV-I;
- Uncontrolled hypertension: systolic blood pressure >160 mmHg and diastolic blood pressure >95 mmHg;
- Triglycerides >400 mg/dL;
- Aspartate aminotransferase or alanine aminotransferase >2.5 times the upper limit of normal (ULN);
- Creatine phosphokinase >3 times the ULN;
- Patients on a weight loss program with ongoing weight loss, or starting an intensive exercise program within 4 weeks of starting the study;
- Use of any investigational drug within 30 days preceding the first dose of study medication; or
- Employment by the research center.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Placebo Comparator
Experimental
Experimental
Arm Label
1; Placebo
2; Oral Hepatic Directed Vesicles (HDV)-Insulin (U-5)
3; Oral Hepatic Directed Vesicles (HDV)-Insulin (U-15)
Arm Description
Patients receive a sugar pill.
Patients receive Oral HDV-Insulin (U-5).
Patients receive Oral HDV-Insulin (U-15).
Outcomes
Primary Outcome Measures
The primary objective of this trial is to compare the reduction in mean glycated hemoglobin levels (HbA1c) between 2 doses of oral HDV-I and placebo in type 2 diabetic patients on background metformin therapy at the end of 18 weeks of treatment.
Secondary Outcome Measures
To evaluate the effects of oral HDV-I versus placebo on the 7-point glucose test
To evaluate the effects of oral HDV-I versus placebo on fasting plasma glucose (FPG) and insulin
To evaluate the effects of oral HDV-I versus placebo on the homeostasis model assessment of insulin resistance (HOMA-IR)and homeostasis model assessment of β-cell function (HOMA-β)
To evaluate the effects of oral HDV-I versus placebo on frequency of hypoglycemic events, body weight, and lipid levels
Full Information
NCT ID
NCT00814294
First Posted
December 23, 2008
Last Updated
May 24, 2021
Sponsor
Diasome Pharmaceuticals
1. Study Identification
Unique Protocol Identification Number
NCT00814294
Brief Title
Study of Two Doses of Oral HDV-Insulin and Placebo With Background Metformin Treatment in Patients With Type 2 Diabetes Mellitus
Official Title
An 18-Week Randomized, Double-Blind, Multicenter, Comparator Study of Two Doses of Oral HDV-Insulin and Placebo With Background Metformin Treatment in Patients With Type 2 Diabetes Mellitus
Study Type
Interventional
2. Study Status
Record Verification Date
May 2021
Overall Recruitment Status
Completed
Study Start Date
December 2008 (undefined)
Primary Completion Date
September 2009 (Actual)
Study Completion Date
September 2009 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Diasome Pharmaceuticals
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The primary objective of this trial is to compare the reduction in mean glycated hemoglobin levels (HbA1c) between 2 doses of oral HDV-I and placebo in type 2 diabetic patients on background metformin therapy at the end of 18 weeks of treatment.
The secondary objectives are:
To evaluate the effects of oral HDV-I versus placebo on the 7-point glucose test, fasting plasma glucose (FPG), insulin, homeostasis model assessment of insulin resistance (HOMA-IR), homeostasis model assessment of β-cell function (HOMA-β), frequency of hypoglycemic events, body weight, and lipid levels; and
To evaluate the safety and tolerability of oral HDV-I.
Detailed Description
This is a multicenter, randomized, double-blind, placebo-controlled study with a washout/stabilization period of up to 12 weeks in duration and an 18-week double-blind treatment period. There will be a total of 8 visits.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes
Keywords
Type 2
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
239 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1; Placebo
Arm Type
Placebo Comparator
Arm Description
Patients receive a sugar pill.
Arm Title
2; Oral Hepatic Directed Vesicles (HDV)-Insulin (U-5)
Arm Type
Experimental
Arm Description
Patients receive Oral HDV-Insulin (U-5).
Arm Title
3; Oral Hepatic Directed Vesicles (HDV)-Insulin (U-15)
Arm Type
Experimental
Arm Description
Patients receive Oral HDV-Insulin (U-15).
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
placebo capsule,0 units, quater in die (QID) for 18 weeks
Intervention Type
Drug
Intervention Name(s)
Oral Hepatic Directed Vesicles (HDV)-Insulin (U-15)
Intervention Description
Oral HDV-I Caps; 15 U; quater in die (QID) for 18 weeks.
Intervention Type
Drug
Intervention Name(s)
Oral Hepatic Directed Vesicles (HDV)-Insulin (U-5)
Intervention Description
Oral HDV-I; Caps; 5 U; quater in die (QID) for 18 weeks.
Primary Outcome Measure Information:
Title
The primary objective of this trial is to compare the reduction in mean glycated hemoglobin levels (HbA1c) between 2 doses of oral HDV-I and placebo in type 2 diabetic patients on background metformin therapy at the end of 18 weeks of treatment.
Time Frame
18 weeks
Secondary Outcome Measure Information:
Title
To evaluate the effects of oral HDV-I versus placebo on the 7-point glucose test
Time Frame
18 weeks
Title
To evaluate the effects of oral HDV-I versus placebo on fasting plasma glucose (FPG) and insulin
Time Frame
18 weeks
Title
To evaluate the effects of oral HDV-I versus placebo on the homeostasis model assessment of insulin resistance (HOMA-IR)and homeostasis model assessment of β-cell function (HOMA-β)
Time Frame
18 Weeks
Title
To evaluate the effects of oral HDV-I versus placebo on frequency of hypoglycemic events, body weight, and lipid levels
Time Frame
18 Weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age 18 to 70 years, inclusive;
Diagnosis of type 2 diabetes mellitus;
Fasting plasma glucose <=250 mg/dL;
BMI <=45 kg/m2;
HbA1c levels as follows at Screening:
On a stable dose of metformin monotherapy with an HbA1c >=7.5% and <=9.5%;
On metformin and 1 other OAD (excluding TZD, exenatide, or insulin) with an HbA1c >=6.8% and <=9.0%;
Naïve to antidiabetic therapy or have not been on a stable dose of metformin monotherapy for <12 weeks with an HbA1c >=8.0% and <=10.5%;
Understanding of the study procedures and agreement to participate in the study, giving written informed consent;
Women may be enrolled if all of the following criteria (in addition to the above criteria) are met:
They are not pregnant (women of childbearing potential must have a negative serum pregnancy test at Visit 1);
They are not breast-feeding;
They do not plan to become pregnant during the study; and
They have had a hysterectomy or tubal ligation 6 months prior to the study, have been post-menopausal for 1 year, or will practice a method of birth control throughout the study.
Exclusion Criteria:
History of type 1 diabetes and/or history of ketoacidosis;
History of chronic (>2 months) use of insulin therapy or recent initiation of insulin use intended for chronic administration;
Use of TZD (pioglitazone or rosiglitazone) or exenatide within 3 months prior to Screening;
Use of prescription or over the counter weight loss agents within 1 month prior to Screening;
Use of any lipid-altering, antihypertensive, and other chronic use medication not stable for 1 month prior to Screening;
Use of any medication that may alter blood glucose analyses;
Any serious disorder including cardiac, pulmonary, hepatic, uncontrolled endocrine/metabolic, hematologic/oncologic (within the last 5 years), neurologic, and psychiatric diseases that would interfere with the conduct of the study or interpretation of the data;
Require regular use of medication that interferes with the oral absorption and/or metabolism of insulin or metformin;
History of pancreatitis;
History of acquired immune deficiency syndrome or human immunodeficiency virus;
History of drug or alcohol abuse within the past 2 years;
Hospitalization for any cause within 14 days prior to the study;
History of an allergic or toxic response to oral HDV-I;
Uncontrolled hypertension: systolic blood pressure >160 mmHg and diastolic blood pressure >95 mmHg;
Triglycerides >400 mg/dL;
Aspartate aminotransferase or alanine aminotransferase >2.5 times the upper limit of normal (ULN);
Creatine phosphokinase >3 times the ULN;
Patients on a weight loss program with ongoing weight loss, or starting an intensive exercise program within 4 weeks of starting the study;
Use of any investigational drug within 30 days preceding the first dose of study medication; or
Employment by the research center.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Len Rosenberg, PhD, RPh
Organizational Affiliation
Diasome Pharmaceuticals
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
David Orloff, MD
Organizational Affiliation
Medpace, Inc.
Official's Role
Study Director
Facility Information:
City
Muscle Shoals
State/Province
Alabama
ZIP/Postal Code
35661
Country
United States
City
Litchfield Park
State/Province
Arizona
ZIP/Postal Code
85340
Country
United States
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85712
Country
United States
City
Concord
State/Province
California
ZIP/Postal Code
94520
Country
United States
City
Paramount
State/Province
California
ZIP/Postal Code
90723
Country
United States
City
Sacramento
State/Province
California
ZIP/Postal Code
95825
Country
United States
City
San Mateo
State/Province
California
ZIP/Postal Code
94401
Country
United States
City
Stockton
State/Province
California
ZIP/Postal Code
95204
Country
United States
City
Valley Village
State/Province
California
ZIP/Postal Code
91607
Country
United States
City
Walnut Creek
State/Province
California
ZIP/Postal Code
94598
Country
United States
City
Chiefland
State/Province
Florida
ZIP/Postal Code
32626
Country
United States
City
Fort Lauderdale
State/Province
Florida
ZIP/Postal Code
33308
Country
United States
City
Palm Harbor
State/Province
Florida
ZIP/Postal Code
34684
Country
United States
City
Pembroke Pines
State/Province
Florida
ZIP/Postal Code
33029
Country
United States
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30308
Country
United States
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30322
Country
United States
City
Topeka
State/Province
Kansas
ZIP/Postal Code
66606
Country
United States
City
Lexington
State/Province
Kentucky
ZIP/Postal Code
40504
Country
United States
City
Paducah
State/Province
Kentucky
ZIP/Postal Code
42003
Country
United States
City
Brockton
State/Province
Massachusetts
ZIP/Postal Code
02301
Country
United States
City
Picayune
State/Province
Mississippi
ZIP/Postal Code
39466
Country
United States
City
Omaha
State/Province
Nebraska
ZIP/Postal Code
68114
Country
United States
City
Staten Island
State/Province
New York
ZIP/Postal Code
10301
Country
United States
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45236
Country
United States
City
Delaware
State/Province
Ohio
ZIP/Postal Code
43015
Country
United States
City
Zanesville
State/Province
Ohio
ZIP/Postal Code
43701
Country
United States
City
Beaver
State/Province
Pennsylvania
ZIP/Postal Code
15009
Country
United States
City
Kingsport
State/Province
Tennessee
ZIP/Postal Code
37660
Country
United States
City
Corpus Christi
State/Province
Texas
ZIP/Postal Code
78404
Country
United States
City
El Paso
State/Province
Texas
ZIP/Postal Code
79935
Country
United States
City
Houston
State/Province
Texas
ZIP/Postal Code
77074
Country
United States
City
Hurst
State/Province
Texas
ZIP/Postal Code
76054
Country
United States
City
Odessa
State/Province
Texas
ZIP/Postal Code
79761
Country
United States
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78237
Country
United States
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84124
Country
United States
City
Manassas
State/Province
Virginia
ZIP/Postal Code
20110
Country
United States
City
Virginia Beach
State/Province
Virginia
ZIP/Postal Code
23454
Country
United States
City
Renton
State/Province
Washington
ZIP/Postal Code
98055
Country
United States
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53209
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Study of Two Doses of Oral HDV-Insulin and Placebo With Background Metformin Treatment in Patients With Type 2 Diabetes Mellitus
We'll reach out to this number within 24 hrs